Philip Galapon, MD
Family Medicine · Pittsburgh, PANPI 1033370051
Payments from drug & device makers
Across 118 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- USWM, LLC$506
- Amgen$257
- AbbVie$240
- Amarin Pharma, Inc.$191
- Boehringer Ingelheim$170
- Lilly USA, LLC$122
- plus $868 from 22 others
What the payments were for
- Food & beverage$1,84778%
- Gifts$50622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| USWM, LLC | 1 | $506 |
| Amgen | 15 | $257 |
| AbbVie | 20 | $240 |
| Amarin Pharma, Inc. | 12 | $191 |
| Boehringer Ingelheim | 11 | $170 |
| Lilly USA, LLC | 7 | $122 |
| GSK | 7 | $116 |
| Pfizer | 6 | $96 |
| Bayer | 4 | $81 |
| Alkermes, Inc. | 4 | $80 |
| Johnson & Johnson | 3 | $63 |
| AstraZeneca | 4 | $52 |
| Novartis | 2 | $43 |
| Mylan Specialty L.p. | 3 | $42 |
| Melinta Therapeutics, LLC | 2 | $40 |
| Scilex Pharmaceuticals Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Abbott | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $23 |
| Shield Therapeutics Inc | 1 | $21 |
| Redhill Biopharma Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Insulet Corporation | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZIMHI$506
How this compares
$2,354 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 89 | $117,218 |
| JardianceEmpagliflozin | 87 | $89,928 |
| OzempicSemaglutide | 72 | $65,730 |
| EliquisApixaban | 72 | $61,336 |
| MounjaroTirzepatide | 38 | $46,496 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $27,297 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $24,914 |
| FarxigaDapagliflozin Propanediol | 19 | $22,321 |
| LinzessLinaclotide | 28 | $22,005 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $20,750 |
| VascepaIcosapent Ethyl | 25 | $19,508 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $19,141 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 91 | $17,325 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 35 | $16,817 |
| Repatha SureclickEvolocumab | 31 | $16,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $122 | $163,714127 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $170 | $106,118117 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $116 | $72,062121 claims |
| Novo NordiskOzempic | $14 | $65,73072 claims |
| PfizerEliquis | $96 | $61,33672 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort | $52 | $46,04969 claims |
| AbbVieLinzess | $240 | $22,00528 claims |
| Johnson & JohnsonXarelto | $63 | $14,06413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Pittsburgh
- Bryce PalchickPittsburgh$4.7M
- Shari RozenPittsburgh$2.9M
- Nathan BennettPittsburgh$1.6M
- James MorettiPittsburgh$1.5M
- Michael GatesPittsburgh$608K
- Daniel AustinPittsburgh$598K
- Norman KolbPittsburgh$81K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.